Background: Most patients with common variable immunodeficiency (CVID) present with severely reduced switched memory B-cell counts, and some display an increase of CD21 low B-cell counts (CVID 21low), whereas others do not (CVID 21norm). Altered B-cell receptor (BCR) signaling might contribute to the defective memory formation observed in patients with CVID. Objective: We sought to investigate canonical nuclear factor of k light chain (NF-kB) signaling in B cells from patients with CVID as a central pathway in B-cell differentiation. Methods: Degradation of inhibitor of kBa (IkBa) and p65 phosphorylation, nuclear translocation of p65, and regulation of target genes and cell function were investigated after different modes of B-cell stimulation. Results: BCR-mediated canonical NF-kB signaling was impaired in all mature naive CVID-derived B cells. This impairment was more profound in naive B cells from CVID 21low patients than CVID 21norm patients and most pronounced in CD21 low B cells. The signaling defect translated
Background: Most patients with common variable immunodeficiency (CVID) present with severely reduced switched memory B-cell counts, and some display an increase of CD21 low B-cell counts (CVID 21low), whereas others do not (CVID 21norm). Altered B-cell receptor (BCR) signaling might contribute to the defective memory formation observed in patients with CVID. Objective: We sought to investigate canonical nuclear factor of k light chain (NF-kB) signaling in B cells from patients with CVID as a central pathway in B-cell differentiation. Methods: Degradation of inhibitor of kBa (IkBa) and p65 phosphorylation, nuclear translocation of p65, and regulation of target genes and cell function were investigated after different modes of B-cell stimulation. Results: BCR-mediated canonical NF-kB signaling was impaired in all mature naive CVID-derived B cells. This impairment was more profound in naive B cells from CVID 21low patients than CVID 21norm patients and most pronounced in CD21 low B cells. The signaling defect translated into reduced induction of Bcl-xL and IkBa, 2 bona fide target genes of the canonical NF-kB pathway. CD40 ligand-and Tolllike receptor 9-mediated signaling were less strongly altered. Signaling in CD21 low B cells but not CD21 1 B cells of patients with HIV was similarly affected. Conclusion: Combined with the previous description of disturbed Ca 21 signaling, the discovery of NF-kB signaling defects, especially in CVID 21low patients, suggests a broad underlying signaling defect affecting especially BCR-derived signals. Given the immune phenotype of monogenic defects affecting Ca 21 and NF-kB signaling, the latter is more likely to contribute to the humoral deficiency. The strongly disturbed BCR signaling of CD21 low B cells is characteristic for this cell type and independent of the underlying disease. Common variable immunodeficiency (CVID) is a highly variable antibody deficiency syndrome with a heterogeneous and often undefined genetic background. 1, 2 Common to most patients is a severe reduction in circulating class-switched memory B-cell and plasma cell numbers in the bone marrow. 3, 4 Immunoglobulin-secreting plasma cells develop in extrafollicular areas after antigen-induced activation in T-independent immune responses from B cells activated by pattern recognition receptors, such as Toll-like receptors (TLRs), or in T-dependent immune responses stimulated by T H cells activating CD40 and cytokine receptors in germinal centers (GCs). The GC reaction also leads to formation of high-affinity class-switched memory B cells that persist in human subjects for decades and develop rapidly into plasma cells secreting high-affinity antibodies after reactivation by antigen. 5, 6 Defects in patients with CVID underlying the humoral immunodeficiency frequently affect memory and plasma cell differentiation. 7, 8 According to EUROClass, 9 a flow cytometrybased classification of CVID, one subgroup of patients with CVID is characterized by the increased presence of a rare subset of circulating B cells expressing only low levels of CD21 (>10% of CD21 low B cells; CVID 21low) constituting more than 10% of peripheral B cells, which is rare in other patients with CVID (<10% of CD21 low B cells; CVID 21norm) and healthy control subjects.
In addition to increased infection susceptibility, CVID 21low patients frequently have autoimmune and lymphoproliferative manifestations. A similar expansion of CD21 low B cells has also been described in patients with chronic HIV infections or in patients with autoimmune disorders, such as systemic lupus 15 On antigen binding to the BCR, phosphorylation of phospholipase Cg2 (PLCg2) leads to production of inositol trisphosphate (IP3), inducing Ca 21 flux, and diacylglycerol (DAG), which activates protein kinase Cb (PKCb) and leads to activation of the canonical nuclear factor of k light chain (NF-kB) pathway by phosphorylating the inhibitor of kB kinase (IKK) complex. The inhibitor of kBa (IkBa) is phosphorylated, ubiquitinylated, and degraded, and p65/p50 dimers are released and enter the nucleus to activate gene transcription. The canonical NF-kB pathway plays a central role in B-cell differentiation, maintenance and function in mice. [16] [17] [18] [19] [20] Given the altered Ca 21 activation in these patients, we analyzed the canonical NF-kB pathway in patients with CVID with reduced switched memory B cells. We found a significantly reduced NF-kB signal, with the strongest impairment in CVID 21low patients. The severely impaired canonical NF-kB signal in CD21 low B cells was characteristic of this cell stage and not genetically determined because it was seen similarly in CD21 low B cells of patients with HIV. However, the reduced BCR signal affecting both Ca 21 and the canonical NF-kB signal in naive CD21
1 B cells was unique to the patients with CVID and might suggest an underlying genetic predisposition affecting B-cell activation.
METHODS

Cell isolation and cultivation
PBMCs were isolated from EDTA blood by using Ficoll density centrifugation and cultivated in RPMI 10% FCS.
B-cell activation and survival
IkBa degradation, phosphorylation of p65, phospho-IkBa, and phospho-PLCg2 were determined by using intracellular flow cytometry, as described previously. 21 PBMCs were left untreated or stimulated with 15 mg/mL F(ab)9 2 goat anti-human IgM (SouthernBiotech, Birmingham, Ala), 5 mg/mL CpG-ODN 2006 (InvivoGen, Toulouse, France), recombinant CD40 ligand (CD40L), or 200 ng/mL phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich, St Louis, Mo), as indicated. For some experiments, cells were pretreated with the proteasome inhibitor MG132 (10 mmol/L) for 4 hours. Cells were fixed by means of addition of Cytofix and permeabilized with Perm Buffer III (both from BD Biosciences, San Jose, Calif), according to the manufacturers' instructions. After permeabilization, cells were stained with the appropriate antibodies and measured on an LSR Fortessa (BD Biosciences). For upregulation of IkBa and Bcl-xL, cells were stimulated for 36 hours and treated as described above. Activation markers were determined after cultivation of PBMCs with 10 mg/mL anti-human IgM for 36 hours. Cells were washed and stained with the respective surface markers. For B-cell survival, naive B cells were isolated from PBMCs by using the MACS Naive B Cell Isolation Kit II (Miltenyi Biotech, Bergisch Gladbach, Germany). Cells were cultivated for 17 hours in the absence or presence of 10 mg/mL anti-IgM, harvested, counted, and stained for flow cytometric assessment of apoptosis.
All 
Confocal microscopy
For nuclear translocation of p65, isolated B cells were left untreated or stimulated with 20 mg/mL anti-human IgM for 2 hours and CD40L for 30 minutes. Cells were fixed with 4% paraformaldehyde, washed, and settled onto slides. After blocking (10% goat serum/2% immunoglobulin) and surface staining with CD21, permeabilization with 0.3% Triton was followed by anti-p65 and anti-IgM staining. Nuclei were stained with H€ ochst33342. Images were taken on a Zeiss laser scanning microscope, LSM710 (Carl Zeiss, Jena, Germany) and evaluated and processed with Zeiss ZEN black software.
Additional information can be found in the Methods section and in Figs E1 and E2 in this article's Online Repository at www.jacionline.org. 2 B cells. The degree of impairment varied between patients: whereas in CVID 21norm patients (patients 17 and 22) it was near normal, IkBa degradation was severely reduced, especially in CVID 21low patients (patients 4, 5, and 10; Fig 1, A) . The differentiation of CD21 1 and CD21 low B cells revealed a comparable basal IkBa expression in unstimulated CD21
RESULTS
Reduced
1 B cells of HDs and of CVID 21low and 21norm patients, but this was significantly decreased in patient-derived CD21 low B cells (Fig 1, B) . After BCR stimulation for 35 minutes, the mean fluorescence intensity (MFI) of IkBa decreased in CD21 1 B cells but remained significantly higher in B cells from patients with CVID compared with HDs. IkBa expression in CD21 low B cells hardly decreased after stimulation (Fig 1, C) , although the BCR is equally expressed on patients' CD21 1 B cells and even higher on CD21 low B cells. 13 We determined the ratio of the MFI of IkBa after and (Fig 1, D) .
Because of the more severe phenotype of B cells from CVID 21low patients, all further experiments were performed on B-cell subpopulations derived from these patients.
IkBa protein levels were examined up to 180 minutes after BCR stimulation to exclude that reduced IkBa degradation in B cells from patients with CVID was caused by delayed signaling. In all 3 examined B-cell subpopulations, the IkBa ratio was decreased after 35 minutes and further decreased after 90 minutes, which was more or less stable during the next 90 minutes. However, the pattern of defective NF-kB signaling was stable over time, with significantly reduced IkBa degradation in CD21
1 B cells compared with HDs and even lower responses in CD21 low B cells at any analyzed time point (Fig 1, E) .
CVID 21low patients with and without immunosuppressive therapy and patients with subcutaneous and intravenous immunoglobulin substitution (see Table E1 ) were compared to exclude a potential influence on NF-kB activation. We observed no significant differences between the different groups, implying that these medications did not cause the observed defect in NF-kB activation (data not shown).
Failure of regular p65 phosphorylation and translocation after BCR stimulation
Next, BCR-mediated p65 activation was analyzed. p65 phosphorylation was significantly decreased in CD21
1 B cells of CVID 21low patients compared with CD21
1 B cells of HDs and not detectable in CD21 low B cells, corroborating the results for IkBa degradation (Fig 2, A) . After release from IkBa, p65/ p50 heterodimers enter the nucleus to activate gene transcription. Thus nuclear translocation of p65 after BCR stimulation was determined by means of immunofluorescence. In the unstimulated state p65 is predominantly located in the cytoplasm (Fig  2, B) . In about 40% of naive CD21 1 B cells from HDs, p65 translocated to the nucleus after anti-IgM stimulation, whereas in CD21 1 and CD21 low B cells from CVID 21low patients, nuclear translocation of p65 was severely reduced, confirming the impairment in NF-kB activation downstream of the BCR.
Activation of PKCb is not generally affected
Although NF-kB and Ca 21 activation (see Fig E3, A, in this article's Online Repository at www.jacionline.org) was reduced, phosphorylation of PLCg2 was intact in B cells of patients with CVID (see Fig E3, B) , suggesting that the canonical NF-kB signal after BCR stimulation is affected downstream of PKCb. Therefore cells were stimulated with PKC-activating PMA. Nearly complete IkBa degradation was induced in all B-cell subpopulations (see Fig E4, A, in this article's Online Repository at www.jacionline.org). The higher MFI of IkBa in CD21 low B cells after stimulation originated from a small proportion of cells that did not properly degrade the inhibitory protein, but it was not due to a generally impaired signal downstream of PKCb, as seen in CARD11-deficient B cells (see Fig E4, B) . This implied an overall integrity of the canonical NF-kB signaling pathway downstream of PKCb in B cells of patients with CVID.
Preactivation contributes to reduced IkBa basal levels in CD21 low B cells
Reduced IkBa protein levels in CD21 low B cells were associated with increased baseline phosphorylation of IkBa compared with CD21
1 B cells (Fig 3, A) , implying that the preactivated state of these cells 13 might contribute to reduced IkBa expression through its degradation. Treatment with the proteasome inhibitor MG132 has little effect on total IkBa levels 22 in all B-cell populations (data not shown) but increased the detection of phosphorylated IkBa in unstimulated CD21 1 B cells of healthy control subjects and patients but not CD21 low B cells (Fig 3, B) . After IgM stimulation, IkBa phosphorylation increased further in the presence of the inhibitor. Also, this effect was reduced especially in CD21 low B cells of the patients, corroborating the notion of impaired BCR-induced NF-kB signaling.
Analysis of NFKBIA (encoding IkBa) RNA expression in sorted B-cell subpopulations did not reveal significant differences in CD21 low B cells compared with CD21 1 B cells (data not shown), indicating that the increased IkBa phosphorylation and reduced basal IkBa protein levels in CD21 low B cells did not translate into increased transcription of NF-kB target genes (see also below).
CD40-and TLR9-induced NF-kB signaling is altered in B cells from patients with CVID
To test whether the NF-kB pathway downstream of other receptor pathways than the BCR was affected, we analyzed the degradation of IkBa after CD40 activation. CD40 triggers the canonical NF-kB pathway independent of PKCb-caspase recruitment domain family member 11 (CARD11)/mucosaassociated lymphoid tissue lymphoma translocation protein 1 (MALT1)/B-cell CLL/lymphoma 1 (BCL10) by using different TNF receptor-associated factors (TRAFs), TAK1-binding protein (TAB), and TGF-b-activated kinase 1 (TAK1). 23 Stimulation with trimeric CD40L at optimal concentrations (1:500) for 15 minutes induced a nearly complete degradation of IkBa in all CD21 1 and CD21 low B cells from HDs and patients, although the MFI of IkBa after stimulation was still slightly higher in patients' CD21 1 B cells (Fig 4, A) . In both patient-derived B-cell subpopulations, the IkBa ratio was significantly increased compared with that in HDs in CD21 low B cells mainly because of the lower baseline expression of IkBa (Fig 4, A) . When CD40L was titrated to suboptimal concentrations, the response was detectably reduced in CD21 low B cells but not in CD21 1 B cells of patients with CVID (Fig 4, B) . Nuclear translocation of p65 was strongly induced after CD40 stimulation in CD21 1 B cells of HDs but reduced in CD21 1 and CD21 low B cells of patients (Fig 4, C) . Thus the CD40-mediated canonical NF-kB activation was affected in B cells from patients with CVID, although to a lesser degree than BCR-mediated activation. CD40 expression was comparable in patients' CD21
1 B cells and slightly reduced in CD21 low B cells (data not shown), which might contribute to the altered response in CD21 low but not CD21
1 B cells. ) and CD21 1 (red) or CD21 low B cells of CVID 21low patients (n 5 6), as described in detail in this article's Online Repository. *P < .05, **P < .01, and ***P < .001.
Also, the signaling cascade downstream of TLR9 involves the canonical NF-kB pathway. Therefore we determined TLR9-mediated IkBa degradation. Although IkBa was clearly degraded on CpG stimulation, the ratio of the MFI of IkBa revealed that IkBa degradation was significantly decreased in CD21
1 and especially CD21 low B cells of CVID 21 low patients compared with HDs (Fig 5) . Similar to the results after CD40 stimulation, this reflected predominantly the reduced baseline expression of IkBa in CD21 low B cells but also a partially impaired degradation after TLR stimulation.
Reduced expression of NF-kB target genes and increased apoptosis after BCR stimulation
To determine the effect of the impaired activation of NF-kB signals after BCR stimulation, we examined the induction of the bona fide target genes BCLXL (BCL2L1) and IkBa (NFKBIA) 19, 20 after anti-IgM stimulation for 36 hours. Induction of Bcl-xL was strongly reduced in patients' CD21
1 B cells compared with CD21
1 B cells of HDs and was absent in CD21 low B cells (Fig 6, A) . Upregulation of IkBa was absent in both CD21 1 and CD21 low B cells of the patients, confirming impairment of the canonical NF-kB pathway downstream of the BCR (Fig 6, B) .
Because Bcl-xL is an important NF-kB-induced antiapoptotic protein, 24, 25 we were interested in regulation of apoptosis in patients' B-cell subpopulations. Annexin V staining was determined in isolated B cells after 17 hours of in vitro culture in the absence or presence of anti-IgM. CD21
1 B cells and especially CD21 low B cells of the patients were more prone to undergo apoptosis, fitting a reduced prosurvival NF-kB signal (Fig 6, C) .
In addition, NF-kB signals contribute to the upregulation of activation markers, such as CD69, intercellular adhesion molecule 1 (ICAM-1), and CD25. 26, 27 After gating on 49-6-diamidino-2-phenylindole (DAPI)-negative cells, we found profoundly impaired upregulation of CD69, ICAM-1, and CD25 in CD21 Disturbed canonical NF-kB signaling is also seen in CD21 low B cells derived from patients with HIV
To investigate whether the severely disturbed NF-kB signal in CD21 low B cells is due to an underlying genetically determined immunodeficiency or a general nongenetic biochemical feature of CD21 low B cells, we used CD21 low B cells of 6 patients with HIV without antiretroviral treatment (see Table E2 in this article's Online Repository at www.jacionline.org). In contrast to patients with CVID, in whom CD21 low B cells usually resemble naive B cells according to the expression of CD27 and IgM, in patients with HIV, CD21 low B cells can be assigned to different B-cell subpopulations depending on the expression of CD27 and the BCR isotype (and own unpublished observations). 10 To allow for direct comparison with naive-like CD21 low B cells in patients with CVID, we focused on IgD 1 /CD27 2 CD21 low B cells in patients with HIV. As observed for CVID-derived CD21 low B cells, after short-term BCR stimulation for 35 minutes, IkBa degradation was significantly decreased compared with that seen in CD21 1 counterparts of HDs and patients (Fig 7, A) . In line with our previous findings in patients with CVID, IkBa degradation was strongly induced after CD40 stimulation for 15 minutes, but at low concentrations of CD40L, the MFI of the residual IkBa expression was significantly higher in CD21 low B cells compared with that in CD21 1 cells (Fig 7, B) . Thus reduced IkBa degradation in CD21
1 cells was only seen in patients with CVID and might suggest a disease-associated impairment, whereas the severe deficiency in canonical NF-kB activation in CD21 low B cells is a common feature of CD21 low B cells.
Patients with NFKB1 haploinsufficiency present with the CVID smB2 21 low phenotype Last year, we described 3 familial cases of CVID with haploinsufficiency of p50 caused by heterozygous mutations in NFKB1, 28 and autosomal dominant mutations in NFKB2 have been described in patients with a CVID-like syndrome. 29, 30 Eight low patients. C, Representative pictures of p65 nuclear translocation (yellow) with CD21 costaining (red) and distribution of the percentage of p65 in HDs (n 5 6) and CVID 21 low patients (n 5 6). *P < .05, **P < .01, and ***P < .001. of 15 CVID 21low patients and 3 of 8 CVID 21norm patients have been analyzed by panel or whole-exome sequencing: no obvious disease-causing mutation/variant has been identified in NFKB1, NFKB2, NFKBIA, IKBKB, and IKBKG.
To corroborate a potential relation between the B-cell phenotype and disturbed NF-kB activation, we analyzed 2 published 28 and 3 additional adults with NFKB1 mutations, presumably resulting in haploinsufficiency. All presented with a reduction of switched memory B-cell counts and a substantial accumulation of CD21 low B cells in the peripheral blood, representing the CVID smB2 21low phenotype (Table I) .
DISCUSSION
Here we report impaired activation of the canonical NF-kB signaling pathway in B cells of a subgroup of patients with CVID with disturbed B-cell memory formation, as demonstrated by reduced degradation of IkBa, impaired phosphorylation and nuclear translocation of p65, and decreased upregulation of the NF-kB-induced proteins Bcl-xL and IkBa. Although in CD21 1 B cells of CVID 21low patients a residual NF-kB signal could be observed and seems to be associated with the underlying immunodeficiency, NF-kB activation in CD21 low B cells was almost absent. This defect was linked to the specific B-cell stage because naive-like CD21 low B cells in HIV-viremic patients demonstrated a similar impairment. Thus the signaling defect in CD21 low B cells might be due to a regulatory response to chronic activation by an inflammatory environment, as in complex immune dysregulation in patients with CVID, 9,31 viremia in patients with HIV, 32 and patients with other chronic infections.
33,34
The canonical NF-kB activation was mainly affected downstream of the BCR but also downstream of CD40 and less severely after CpG treatment. Thus there is a general defect in canonical NF-kB activation, which seems to correlate with the strength of the external signal and was overcome by a higher concentration of CD40L or stimulation by PMA, although not after BCR stimulation.
Cell stage specifically disturbed phosphorylation of IKK and degradation of IkBa in connection with normal PLCg2 phosphorylation downstream of BCR activation, and a normal PMA-induced NF-kB signal has been described for murine B1a cells. 35, 36 The authors proposed that decreased expression of Vav and increased expression of heat shock protein (hsp) 70 reduced the inhibition of phosphatases and resulted in defective NF-kB activation. 36 However, our preliminary results show that the general inhibition of phosphatases did not improve NF-kB signaling in CD21 low B cells. Instead, increased IkBa phosphorylation at baseline and the lacking response to proteasome inhibition or BCR signals suggest that in CD21 low B cells chronic activation can uncouple NF-kB pathway activation at this late stage from target gene transcription. Thus different mechanisms might be responsible for a similar pattern of altered signaling in CD21 low B cells and B1a cells, which share activated status with CD21 low B cells. 13 Although we could not identify the exact mechanism that failed during canonical NF-kB signaling, also the fact that BCR, CD40, and TLR signals are involved supports the idea that a late step during NF-kB activation is affected. On the other hand, it is important to note that B cells from CVID 21 low patients show additional signaling alterations. In all mature B cells of CVID 21 low patients, BCR-induced Ca 21 mobilization was impaired, and as for NF-kB, the more severe impairment was observed in CD21 low B cells. 15 Store-operated Ca 21 entry was selectively affected, 15 but vice versa, this does not explain an impaired canonical NF-kB signal given the fact that ORAI1-deficient B cells show a normal canonical NF-kB signal after BCR stimulation (data not shown). These data suggest that the disturbed NF-kB signal we observed is only part of a broader signaling deficiency in B cells of CVID 21low patients, and consequently, we could not find mutations in known genes affecting specifically the activation of NF-kB. More extensive studies will be necessary to analyze the role of persistent inflammation in these patients on canonical NF-kB and also Ca 21 signaling. (Fig 6, A) and IkBa (Fig 6, B) . C, Percentage of Annexin V 2 /49-6-diamidino-2-phenylindole (DAPI) 2 B cells. D, Ratio of the MFI of CD69, ICAM-1, and CD25 with and without anti-IgM stimulation. *P < .05, **P < .01, and ***P < .001.
The role of specific signaling pathways in the differentiation of human memory B cells and plasma cells has not been fully elucidated. Severe deficiency in store-operated Ca 21 entry because of ORAI1 or stromal interaction molecule 1 (STIM1) deficiency causes a combined immunodeficiency because of strong T-cell impairment 37, 38 but did not affect immunoglobulin levels and memory B-cell formation (own unpublished data). 37 In contrast, in patients with homozygous defects in NF-kB signaling components, such as CARD11, 21, 39 MALT1, 40 BCL10, 41 and IKKb, [42] [43] [44] memory B-cell formation and antibody production are severely impaired, suggesting a more prominent role of NF-kB than Ca 21 signaling in the differentiation of long-lived B-cell memory. This is supported by murine studies investigating the role of NF-kB and different NF-kB subunits in B-cell development and maturation and activation in general 18, 19, 45 and, more specifically, in plasma cell and memory B-cell formation. 46 Within the GC, only a small proportion of centrocytes is subjected to NF-kB signaling. 47, 48 However, ablating c-Rel, one of the NF-kB transcription factors involved in the canonical pathway, in GC B cells disturbed GC maintenance and affinity maturation, and in the absence of p65, GCs formed, but plasma cell development was impaired. 49 Additionally, NF-kB is required for antigen-specific B-cell activation initiating the GC reaction. 20 Damdinsuren et al 50 have shown that a single round of BCR stimulation induces a first NF-kB signal that primes B cells to receive T-cell help. Thus it is tempting to speculate that impaired canonical NF-kB signaling in mature B cells, especially of CVID 21 low patients, contributes to defective B-cell activation and survival and disturbs T-cell help and thus the outcome of the GC reaction, leading to hypogammaglobulinemia and reduced class-switched memory B cells. The prominent role of this signaling pathway in the differentiation of B cells was recently underlined by the discovery of NFKB1-haploinsufficient patients with CVID. 27 Interestingly, all investigated patients not only presented with a defective class-switched memory B-cell compartment but also with a significant expansion of CD21 low B cells, suggesting either an indirect link through the chronic inflammation observed in most of these patients or even a direct link of the disturbed canonical NF-kB activation and expansion of CD21 low B cells.
In summary, we were able to demonstrate that the canonical NF-kB pathway is disturbed, especially in B cells of CVID 21low patients. This might result from a currently undefined genetic predisposition, which affects especially the BCR signal downstream of PLCg2 but also the canonical NF-kB activation by TLR9 and CD40 signals. This disturbed canonical NF-kB pathway in CD21
1 B cells was associated with the underlying disease and might itself contribute to the immunodeficiency observed in the affected patients. CD21 low B cells show an even more severe impairment of these signals independent of their origin. This observation suggests a cell stage-specific regulatory mechanism abrogating full activation of this population. An impaired NF-kB signal, as observed in the NFKB1-haploinsufficient patients, might itself contribute to the expansion of CD21 low B cells. An improved understanding of these mechanisms might help the dissection of regulatory signaling properties during B-cell activation and their potential therapeutic application in patients with autoimmune disease, as well as immunodeficiency. d This signaling defect might contribute to the poor memory formation in these patients.
d CD21 low B cells, independent of their origin, showed the strongest impairment, suggesting an additional cell stage-associated regulatory mechanism.
METHODS Patients
All investigations were performed after patients had signed the informed consent form. The study was approved by the institutional review board (FR251/13 and 66/13) according to the declaration of Helsinki. The diagnosis of CVID was based on the 1999 European Society for Immunodeficiencies criteria as follows: a marked decrease in IgG levels (> _2 SDs les than the mean for age) and a marked decrease in at least 1 of the isotypes IgM or IgA, as well as (1) 
Molecular biology
RNA of fluorescence-activated cell-sorted B-cell subpopulations was isolated by using the RNeasy Mini Kit (Qiagen, Venlo, The Netherlands), and cDNA was generated by use of Superscript II Reverse Transcriptase (Life Technologies, Carlsbad, Calif). Quantitative RT-PCR was performed with SBYR Green (Roche Diagnostics, Mannheim, Germany), and primer pairs were used as follows: IkBa, forward TGAAAGACGAGGAGTACGAGCAG and reverse CTTCATGGATGATGGCCAAGTGCA; RPLP0, forward CGG GCCCGAGAAGACCT and reverse TTGTACCCGTTGATGATAGAATGG (Apara Bioscience GmbH, Denzlingen, Germany).
Statistics
Data were analyzed with GraphPad Prism 6 software (GraphPad Software, La Jolla, Calif). Normal distribution was analyzed, and statistical differences were determined by using the paired t test, the unpaired t test, the Wilcoxon matched pairs test, or the Mann-Whitney test. Differences were considered statistically significant at P values of less than .05. Data are shown as means with SDs.
Automatic scoring algorithm of p65 nuclear translocation in human B cells from confocal microscopy images
In the first step cell outlines were determined from the transmitted light differential interference contrast (DIC) images. Because a transmitted light image usually lacks enough contrast to allow direct segmentation and intensity-based methods usually also fail to separate the cells from the background, we made use of the naturally appearing shadows around each cell that characterize a DIC image. We applied a shadow-casting algorithm from the ImageJ (National Institutes of Health, Bethesda, Md) toolkit to extend the endogenous shadows of the DIC images. We cast shadows from 8 directions equally distributed at 458 angles, thus creating 8 images of slightly rotated shadows around each cell. These 8 images were then combined, and the resulting image was segmented based on intensity values. The cells were filtered according to their diameter, which was set within the range of the mean cell size plus or minus the typical variance to identify cells that were forming clusters that the segmentation algorithm did not separate, as well as to exclude small-cell debris.
The nuclear outline was determined from the Hoechst fluorescence image by using the Otsu thresholding algorithm in ImageJ (water-shading algorithm). The segmented nuclei were submitted to the particle-finder algorithm of ImageJ, thus resulting in the outline of each nucleus after proper filtering for size (see the caption of Fig E4) . Additionally, the cell clusters that were identified based on their large size were further segmented according to the number of contained nuclei.
The segmented cells received an ID for further tracking and were further analyzed regarding: (1) IgM (to identify B cells and to exclude non-B-cell contaminants) and (2) CD21 expression (to identify CD21 1 and CD21 low B cells). An automated algorithm selected only the fluorescence signal (both IgM and CD21) above a fourth of the maximum fluorescence intensity in an image that typically represented 2-fold of the background noise. Unspecific labeling because of use of secondary antibodies was excluded by appropriate control measurements because it felt less than the threshold. Because CD21 and IgM labeling is membrane bound, we additionally excluded cells showing a comparable nuclear and cytoplasmic fluorescence signal.
Using this strategy, we further analyzed only B cells in the image plane with a distinct nucleus that could be classified into CD21 1 or CD21 low cells. The whole-cell and nuclear segmentation images were combined to calculate the whole-cell body area, as well as the nuclear area, and to generate a wholecell mask and a nuclear area mask. The p65 distribution ratio was then calculated by multiplying the raw p65 fluorescence images with the mask of identified whole-cell bodies and with the mask of cell nuclei, respectively. The resulting p65 images specific for the identified cells and identified nuclei contain 2 values for each cell: a value of p65 contribution in the whole cell and a value of p65 contribution only to the nucleus. The percentage of nuclear p65 contribution was calculated for each identified cell in each image for each patient or HD for each condition. These values together with the corresponding cellular IDs were summarized in a table, and the frequencies per condition were plotted in a histogram (Fig E2) . These histograms were fitted with the sum of 2 normal distributions (2-peak Gaussian functions), and the corresponding fitted parameters were calculated and used to automatically calculate the portion of cells showing p65 nuclear translocation per condition. The objects were filtered by size to exclude cellular debris. The average size of a human B cell is known to be 80 mm 2 . We set the condition that objects of less than 20 mm 2 are debris. These objects have been excluded from further analysis. B, By using an intensity-thresholding algorithm, fluorescence images of the nuclear staining was segmented, and then the objects were filtered by size to exclude debris and other artifacts: only nuclei with a size of between 15 and 100 mm 2 were taken into account. Cell clusters from DIC images of a size of greater than 180 mm 2 were separated according to the number of contained cell nuclei. C, Results of object segmentation from the DIC images and Hoechst fluorescence images were merged together to further analyze only the objects having plausible B-cell size and only 1 nucleus of plausible size. Each cell received a cell ID for further tracking. D, By using simultaneous IgM fluorescence staining, the identified cells were verified to be B cells, whereas non-B-cell contaminants were excluded from further analysis. Non-B-cell contaminants represented 4.4% 6 1.3% of all imaged cells in patients with CVID and 6.7% 6 1.5% in HDs. Internal intensity references (ie, maximum fluorescence intensity, as well as background and background noise within an image) were used to counteract possible artifacts induced by means of variable acquisition and/or staining conditions typical for confocal microscopy. E, Only the IgM 1 cells were evaluated as far as their CD21 signal is concerned. As previously described, the maximum fluorescence intensity, as well as background and background noise of CD21 staining within an image, were used as reference, to exclude artifacts caused by variable fluorescence signal between images. Only a signal greater than maximal intensity (I max )/2 was considered to indicate CD21 
